10-Q: Oncolytics Biotech Q1 2026: Increased R&D, G&A Costs, Cash Burn Continues

Oncolytics Biotech reported a net loss of $9.24 million for Q1 2026, with significant increases in R&D and G&A expenses, while cash reserves remain a concern for long-term operations.

Summary

• Oncolytics Biotech reported a net loss of $9.24 million for the first quarter ended March 31, 2026, compared to a net loss of $4.71 million in the same period of 2025.
• Total operating expenses rose to $9.28 million from $5.02 million year-over-year, driven by increased Research and Development (R&D) and General and Administrative (G&A) expenses.
• R&D expenses increased by $1.75 million to $4.55 million, primarily due to higher personnel costs (including stock-based compensation) and increased clinical trial expenses for the second-line mCRC study.
• G&A expenses increased by $2.51 million to $4.73 million, largely attributed to higher public company-related expenses (including Domestication costs) and personnel costs.
• The company's cash and cash equivalents stood at $5.49 million as of March 31, 2026, which, combined with potential capital raises, is expected to fund near-term milestones but not operations for at least twelve months, raising substantial doubt about its ability to continue as a going concern.
• Financing activities provided $7.61 million in net proceeds from at-the-market (ATM) offering agreements during the quarter.
• The company completed its domestication from Alberta, Canada, to Nevada, USA, on March 31, 2026.
• Key clinical development updates include the FDA granting Fast Track Designation for pelareorep in second-line mCRC and the initiation of a randomized Phase 2 study in this indication.
• The company is exploring strategic partnerships for its pancreatic cancer program due to the high cost of development.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant increase in net loss and operating expenses, coupled with substantial doubt about the company's going concern status, despite positive clinical trial developments.

Positives

• Received FDA Fast Track Designation for pelareorep in second-line metastatic colorectal cancer (mCRC).
• Launched a randomized Phase 2 study for second-line RAS-mutated MSS mCRC patients in March 2026.
• Reported promising updated clinical data for pelareorep in combination with atezolizumab for third-line squamous cell carcinoma of the anal canal (SCAC), with an ORR of approximately 29%.
• Aligned with the FDA on the design of a pivotal study for second-line or later SCAC.
• Completed analytical testing for cGMP production run and drug product fill.
• Entered into an Open Market Sale Agreement with Jefferies LLC to offer up to $75,000 in common stock.
• Successfully completed the domestication to Nevada, USA, on March 31, 2026.

Negatives

• Reported a net loss of $9.24 million for Q1 2026, a significant increase from $4.71 million in Q1 2025.
• Total operating expenses increased by 85% year-over-year to $9.28 million.
• R&D expenses increased by 63% year-over-year to $4.55 million.
• G&A expenses increased by 113% year-over-year to $4.73 million.
• Cash and cash equivalents of $5.49 million are not sufficient to fund planned operations for at least twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• The company is unable to predict the duration or total costs of its R&D programs or when it may generate revenue.
• The company plans to focus resources on other indications for pelareorep rather than advancing the first-line pancreatic cancer study independently due to high costs.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient cash resources to fund planned operations for at least twelve months.
• The company's ability to continue as a going concern depends on its ability to obtain additional financing, for which there can be no assurance.
• If additional funding is not obtained, the company may need to reduce or delay research and development activities, scale back operations, or pursue strategic alternatives.
• Conducting clinical trials is costly and time-consuming, with inherent uncertainties in timing and cost.
• Future capital requirements are uncertain and depend on various factors including clinical trial results and regulatory outcomes.
• Additional financings may result in dilution to existing shareholders.
• Debt or collaborative financing, if available, may restrict operating flexibility or require relinquishing rights to pelareorep or future revenues.
• Litigation, regardless of outcome, can have an adverse impact due to defense and settlement costs, and diversion of management resources.

Future Outlook

The company expects existing cash resources, even with potential capital raises, to be sufficient for near-term operating milestones but not for at least twelve months of planned operations, raising substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity sales and potential strategic collaborations. The company's clinical development objectives for the remainder of 2026 focus on its randomized second-line mCRC study and evaluating strategic partnership options for PDAC and second-line SCAC programs.

Management Comments

• "Based on our current operating plan, we expect that our existing cash resources, even when considered together with capital that may be raised under our equity distribution arrangements, are sufficient to fund nearterm operating milestones but are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our condensed consolidated financial statements included in this quarterly report."
• "Our ability to continue as a going concern depends on our ability to obtain additional financing to fund ongoing operations."
• "We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval."
• "Until we enter into a transaction agreement with a partner, we do not expect to advance this study on our own and plan to focus our resources on other high-value indications that provide a more efficient path to registration for pelareorep."

Industry Context

StockSavvy.ai notes that Oncolytics Biotech's Q1 2026 results reflect the significant cash burn typical of clinical-stage biopharmaceutical companies. The increased R&D and G&A expenses are consistent with advancing clinical programs and public company operations. The company's focus on gastrointestinal cancers and immunotherapy aligns with major trends in oncology drug development, where combination therapies and platform approaches are gaining traction. However, the substantial doubt about going concern highlights the critical need for successful financing or strategic partnerships in this capital-intensive sector.

Comparison to Industry Standards

• The net loss of $9.24 million for the quarter is substantial but not unusual for a clinical-stage biopharmaceutical company investing heavily in R&D. Many companies in this stage, such as Moderna or BioNTech in their early development phases, reported even larger losses as they advanced their pipeline candidates.
• The increase in R&D expenses to $4.55 million is in line with industry practices for companies advancing late-stage clinical trials. For example, companies developing novel cancer therapies often spend tens of millions annually on clinical trial costs alone.
• The company's cash burn rate and the resulting going concern doubt are common challenges. Many biotechs rely on continuous access to capital markets or strategic partnerships to fund operations until commercialization. Companies like Sarepta Therapeutics have historically navigated similar periods of high cash burn and reliance on financing.
• The reported objective response rates (ORR) for pelareorep in mCRC (33%) and SCAC (29% in third-line) are competitive. For instance, in second-line mCRC, standard-of-care therapies often show ORRs around 10-15%, making Oncolytics' reported results potentially significant if validated in larger trials. Similarly, ORRs in SCAC are typically low, making the reported 29% a notable improvement.
• The company's strategy to seek partnerships for its pancreatic cancer program is a standard approach in the industry, especially for indications requiring substantial investment for Phase 3 trials. This mirrors how many companies partner to share development costs and risks for complex or high-cost indications.

Corporate Governance

Legal Proceedings

• The company is not currently party to any material legal proceedings or claims outside the ordinary course of business, but litigation can have adverse impacts regardless of outcome.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings; positive impact if clinical trial success leads to value appreciation.
• Employees: Continued employment dependent on company's ability to secure financing; stock-based compensation is a key incentive.
• Creditors: No significant debt, but reliance on future financing could impact terms for suppliers.
• Suppliers: Potential impact on payment terms if liquidity becomes severely constrained.

Next Steps

• Continue advancing the randomized second-line mCRC clinical study.
• Monitor patients in the SCAC study and provide a final analysis.
• Finalize the protocol for a pivotal study in second-line or later SCAC.
• Present preliminary analysis of GOBLET Cohort 5 data in the second half of 2026.
• Focus resources on high-value indications for pelareorep rather than advancing the first-line pancreatic cancer study independently.
• Continue engaging with collaborators, academic partners, and stakeholders for PDAC and SCAC programs.
• Focus manufacturing program on preparatory activities for validation of drug substance production process and additional drug product manufacture.
• Continue to analyze additional patent protections and grow the patent portfolio.
• Seek additional capital through the sale of equity securities, strategic collaborations, licensing arrangements, or other financing sources.

Key Dates

Recommendation

Oncolytics Biotech presents a mixed picture. The positive clinical developments, including FDA Fast Track Designation and promising trial data, are significant. However, the substantial increase in net loss, escalating operating expenses, and critical going concern issues due to insufficient cash reserves necessitate a cautious approach. The company's future hinges on its ability to secure substantial additional financing or forge strategic partnerships. Therefore, a 'hold' recommendation is appropriate, pending clearer visibility on financial stability and successful execution of its financing and partnership strategies.

Keywords

Oncolytics Biotech, pelareorep, 10-Q, Q1 2026, biopharmaceutical, immunotherapy, cancer treatment, clinical trials, metastatic colorectal cancer, squamous cell carcinoma of the anal canal, pancreatic cancer, Fast Track Designation, going concern, financing, R&D expenses, G&A expenses